Redeye initiates coverage of A1M Pharma

Report this content

We initiate coverage of A1M Pharma, a early stage biotech company developing a candidate to treat acute kidney injuries in associating with cardiac surgery. With a history of disappointment we now see real potential in A1M Pharma with their new management and strategy as they move towards meeting an unmet medical need. With a strong owner base and positive data from their first phase I study, we see a bright future ahead. 

Read more and download the research update:

Start following companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking.